Biopreservation Market Report 2026

The biopreservation market size has grown rapidly in recent years. It will grow from $6.69 billion in 2025 to $7.58 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to expansion of biobanking activities, growth in clinical research studies, rising use of biospecimens in diagnostics, increased availability of preservation equipment, adoption of standardized storage protocols.

The biopreservation market size is expected to see rapid growth in the next few years. It will grow to $12.43 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increasing demand for regenerative medicine samples, expansion of precision medicine research, rising investments in biorepository infrastructure, growing focus on sample quality assurance, increasing global clinical trial activity. Major trends in the forecast period include increasing adoption of advanced cryopreservation techniques, rising demand for long-term biospecimen storage solutions, growing use of specialized biopreservation media, expansion of centralized biorepository facilities, enhanced focus on sample integrity and traceability.

The rising demand for personalized medicine is playing a major role in driving the growth of the biopreservation market. Personalized medicine targets the treatment of patients based on their specific diseases. These medicines are developed with the support of biobanks, which use biopreservation to store human tissues and cells. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, compared to six approvals in 2022. Therefore, the growing demand for personalized medicine is expected to further boost the biopreservation market in the coming years.

Major companies in the biopreservation market are concentrating on creating advanced solutions, such as cryopreservation technologies, to address the growing need for long-term preservation of complex tissues and organs. Cryopreservation involves protecting biological material at extremely low temperatures (-196°C), either rapidly, as in seed storage, or gradually with controlled dehydration, providing benefits over conventional storage methods by preserving viability and functionality for extended periods. For example, in April 2024, Pluristyx, Inc., a US-based biotechnology firm, introduced PluriFreeze Cryopreservation Media, developed to improve the viability and functionality of human-derived pluripotent stem cells (iPSCs) and other sensitive cell types during freezing and thawing. PluriFreeze is made entirely of synthetic and animal-origin-free (AOF) components. Its low viscosity supports automation and large-scale cell production, while the accompanying DMSO-free wash solution, PluriPrep, enables extended processing times, enhancing cell handling and recovery for research and clinical purposes.

In June 2024, DefiniGEN Ltd., a UK-based biotechnology company, formed a partnership with Atelerix Ltd. to transform drug testing efficiency. Through this collaboration, they aim to improve the efficiency and sustainability of drug testing by allowing the shipment of functional in vitro liver models without relying on cold chain logistics. Atelerix Ltd. is a UK-based biotechnology company dedicated to the development and commercialization of innovative cell-based therapies and regenerative medicine solutions.

Major companies operating in the biopreservation market are Thermo Fisher Scientific Inc., BioLife Solutions Inc., VWR International LLC, BioCision LLC, Lifeline Scientific Inc., Biomatrica Inc., Custom Biogenic System Inc., QIAGEN NV, ThermoGenesis Holdings Inc., MVE Biological Solutions LLC, Taylor-Wharton America Inc., X-Therma Inc., Cesca Therapeutics Inc., Core Dynamics Ltd., The Merck Group, Azenta US Inc., Avantor Inc., Bio-Techne Corporation, Worthington Industries Inc., Chart Industries Inc., Cryoport Inc., LabVantage Solutions Inc., Brooks Automation Inc., BioVault Technical Ltd., Biomatik Corporation, Biostorage Technologies Inc., Arctiko A/S, Eppendorf AG, Panasonic Healthcare Co. Ltd., BioSpherix Ltd.

North America was the largest region in the biopreservation market share in 2025. The regions covered in the biopreservation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopreservation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biopreservation market by increasing costs of imported freezers, liquid nitrogen systems, cryoprotectants, monitoring sensors, and laboratory-grade materials used in storage and preservation. Research institutions and hospitals in North America and Europe are most affected due to reliance on imported preservation equipment, while Asia-Pacific faces cost pressure on consumables and media imports. These tariffs are increasing capital expenditure and operational costs for biobanks. However, they are also supporting local equipment manufacturing, regional media production, and strengthening domestic biopreservation supply chains.

The biopreservation market research report is one of a series of new reports that provides biopreservation market statistics, including biopreservation industry global market size, regional shares, competitors with a biopreservation market share, detailed biopreservation market segments, market trends and opportunities, and any further data you may need to thrive in the biopreservation industry. This biopreservation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biopreservation refers to the use of microorganisms and their metabolic products to enhance food safety and extend shelf life. It is also employed to maintain biospecimens for extended periods while protecting them from damage outside their natural environment. Biospecimens are samples of materials such as urine, blood, tissue, cells, DNA, and others that are stored in a biorepository for future research or used in laboratory testing.

The main types of biopreservation are biopreservation equipment and biopreservation media. Biopreservation equipment comprises instruments such as bio-based therapeutics, clinical biomarkers, cells, viruses, diagnostic biochips, and other tools that maintain the integrity of biospecimens. It is utilized for various biospecimens, including human tissue samples, organs, stem cells, and more. It is employed for therapeutic purposes, research studies, clinical trials, and other applications, and is used by biobanks, gene banks, hospitals, and similar institutions.

The biopreservation market includes revenues earned by entities by providing freezing services, cryogenic storage system services, thawing equipment, and sample refrigeration services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.